Hence, subsequent study employed the Se-Y and FO combination to reverse acquired gefitinib resistance of lung adenocarcinoma HCC827 cells (E746-A750 exon 19 deletion) with elevated GRP78, β-catenin, COX-2, and CSC markers (ABCG2 and CD133), and epithelial–mesenchymal transition (EMT) markers (vimentin and anexelekto (AXL)) [21]. This evidence concerns the gene PTGS2 and lung adenocarcinoma.